A randomized phase II study of paclitaxel (P), carboplatin (C), bevacizumab (B) +/- everolimus (E) in metastatic melanoma (MM): secondary analysis of outcomes in patients who harbor an NRAS mutation NCCTG N0879 (Alliance).

Kottschade, Lisa ,  Allred, Jacob ,  Rumila, K. ,  Markovic, Svetomir ... -  SMR -  -  2017  

Abstract -  Secondary Endpoint -  Primary Analysis -  Experimental -  N0879